Microsoft PowerPoint - L00 Introduction

Previous Page

Next Page

Page Background

CAPOX

KRAS/BRAF wild type:

n=44

CAPOX+C

KRAS/BRAF wild type:

n=46

P

EXPERT-C Trial

CAPOX

All treated (n=81)

CAPOX+C

All treated (n=83)

P

pCR (primary endpoint)

14%

18%

.45

After neoadjuvant chemo

51%

73%

.04

After CRT

76%

89%

.12

At surgery: pCR (+ rCR)

9.1%

10.9%

1.0

PFS at 5 years

68%

75%

.23

Dewdney A et al., J Clin Oncol 2012

Sclafani E et al., Eur J Cancer 2014